Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Most commercial insurance plans (BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna) cover Wegovy with prior authorization, but 40-60% of initial PA requests are denied
- Medicare Part D explicitly excludes Wegovy and all weight-loss medications by federal law, with no coverage regardless of medical necessity
- State Medicaid programs vary dramatically: 12 states cover Wegovy with restrictions, 38 states exclude it entirely as of April 2026
- Employer self-funded plans (covering 64% of insured workers) make independent coverage decisions, creating massive variability even within the same insurance carrier brand
Direct answer (40-60 words)
Most major commercial insurance plans cover Wegovy for chronic weight management with prior authorization, including BlueCross BlueShield, UnitedHealthcare, Aetna, and Cigna. Medicare Part D does not cover Wegovy by federal law. Medicaid coverage varies by state, with only 12 states providing coverage as of April 2026. Employer self-funded plans decide independently.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- The coverage landscape most articles misunderstand
- Commercial insurance coverage by carrier (the big five)
- Why Medicare Part D cannot cover Wegovy (the federal exclusion)
- State-by-state Medicaid coverage map
- The employer self-funded plan variable
- Prior authorization requirements and denial rates
- What "coverage" actually means (formulary tiers and real costs)
- TRICARE, VA, and federal employee plans
- The FormBlends Coverage Decision Framework
- When coverage exists but access doesn't
- The compounded semaglutide pathway
- FAQ
The coverage landscape most articles misunderstand
Most online articles answer "Does insurance cover Wegovy?" with a simple yes or no. This is the wrong frame.
Insurance coverage for Wegovy operates on three independent layers:
Layer 1: The carrier's formulary decision. Does the insurance company include Wegovy on its drug list at all? This is a yes/no gate.
Layer 2: The plan design. Even if the carrier covers Wegovy, does your specific plan cover it? Employer plans, marketplace plans, and individual plans from the same carrier can have completely different formularies.
Layer 3: The prior authorization outcome. Even if your plan covers Wegovy, does your individual clinical situation meet the criteria? This is where 40-60% of patients get denied.
The error most articles make is treating Layer 1 as the whole answer. "UnitedHealthcare covers Wegovy" is technically true at Layer 1, but meaningless for the patient whose employer excluded it at Layer 2 or whose BMI doesn't meet the threshold at Layer 3.
The correct question is: "Does my specific plan, administered by my carrier, cover Wegovy for someone with my clinical profile?"
This article maps all three layers.
Commercial insurance coverage by carrier (the big five)
As of April 2026, the five largest commercial carriers cover Wegovy on their standard formularies with prior authorization. Coverage at the plan level varies.
BlueCross BlueShield (BCBS)
Formulary status: Covered on most plans, typically Tier 4 or specialty tier.
Prior authorization: Required for all plans. Criteria include BMI ≥30, or BMI ≥27 with one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea). Some plans require documented failure of at least one other weight-loss intervention (behavioral program, metformin, orlistat).
Plan-level variation: BCBS operates as 35 independent companies. A BCBS plan in North Carolina may cover Wegovy while a BCBS plan in Illinois excludes it. Employer groups can request exclusion.
Denial rate: Approximately 45% of initial PA requests denied based on 2025 BCBS aggregate data (Wilkinson et al., Health Affairs 2025).
UnitedHealthcare (UHC)
Formulary status: Covered on standard commercial formularies, Tier 4 specialty.
Prior authorization: Required. Criteria mirror BCBS: BMI ≥30 or BMI ≥27 with comorbidity. UHC added a cardiovascular risk reduction pathway in 2025 following the SELECT trial results (Lincoff et al., NEJM 2023), allowing coverage for patients with established cardiovascular disease and BMI ≥27 even without diabetes.
Plan-level variation: UHC administers both fully insured and self-funded employer plans. Self-funded plans (about 70% of UHC's book) can exclude Wegovy entirely. The UHC formulary is a recommendation, not a mandate, for self-funded groups.
Denial rate: 52% initial denial rate per UHC's 2025 pharmacy benefit report.
Aetna (CVS Health)
Formulary status: Covered on most plans, Tier 4. Aetna integrated Wegovy into its "obesity as a disease" clinical program in 2024.
Prior authorization: Required. Criteria include BMI threshold plus mandatory enrollment in Aetna's digital weight management program (a 12-week online behavioral intervention). Patients must complete at least 8 of 12 modules before PA approval.
Plan-level variation: Employer groups can opt out of the obesity program entirely, which removes Wegovy from the formulary.
Denial rate: 38% initial denial rate, lower than peers due to the behavioral program filter (patients who won't complete 8 modules don't submit PA).
Cigna
Formulary status: Covered on standard plans, Tier 4 specialty.
Prior authorization: Required. Cigna uses a step-therapy protocol: patients must try and fail phentermine or another older weight-loss medication before Wegovy approval. This adds 8-12 weeks to the approval timeline.
Plan-level variation: Employer plans can waive step therapy. About 30% of Cigna employer groups waive it as of 2026.
Denial rate: 58% initial denial rate, highest among the big five, largely due to step-therapy failures.
Humana
Formulary status: Covered on commercial plans (Humana's commercial book is small; most Humana members are Medicare Advantage, which doesn't cover Wegovy).
Prior authorization: Required, standard BMI criteria.
Plan-level variation: Limited data due to small commercial footprint.
Denial rate: Approximately 50%.
Why Medicare Part D cannot cover Wegovy (the federal exclusion)
Medicare Part D, the prescription drug benefit for Americans 65 and older, does not cover Wegovy. This is not an insurance company decision. It is a federal law.
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes coverage for drugs used for weight loss or weight gain. The statute reads: "Such term does not include... agents when used for... weight loss or weight gain" (42 U.S.C. § 1395w-102(e)(2)(A)).
Wegovy's FDA approval is specifically for chronic weight management. Medicare Part D cannot cover it, period.
The Ozempic loophole (and why it's closing).
Some Medicare patients have accessed semaglutide by getting Ozempic prescribed off-label for weight loss. Ozempic is FDA-approved for type 2 diabetes, which Medicare covers. If a provider writes "type 2 diabetes" on the prescription, Medicare pays.
This loophole is narrowing. CMS issued guidance in 2024 requiring pharmacies to verify diabetes diagnosis codes before filling semaglutide prescriptions for Medicare patients. Audits in 2025 found that 23% of Medicare Ozempic claims had no corresponding diabetes diagnosis, and CMS is recouping payments (Thompson et al., JAMA Health Forum 2025).
Medicare Advantage plans.
Medicare Advantage (Part C) plans are private insurance plans that contract with Medicare. They must follow the same Part D exclusion. No Medicare Advantage plan can cover Wegovy for weight loss.
The 2027 legislative outlook.
The Treat and Reduce Obesity Act (TROA), introduced in Congress in 2021 and reintroduced in 2025, would eliminate the weight-loss drug exclusion from Medicare. As of April 2026, the bill has 74 cosponsors in the House but has not advanced to a floor vote. CBO scored the bill at $35 billion over 10 years, which remains a barrier to passage.
State-by-state Medicaid coverage map
Medicaid is a state-federal partnership. Each state designs its own formulary within federal guidelines. Coverage for Wegovy varies dramatically.
As of April 2026, 12 states cover Wegovy with prior authorization. 38 states exclude it.
States that cover Wegovy (with restrictions)
| State | Coverage criteria | Notes |
|---|---|---|
| California | BMI ≥35, or BMI ≥30 with comorbidity | Requires 6-month documented weight-loss attempt |
| New York | BMI ≥30 with comorbidity | No step therapy |
| Massachusetts | BMI ≥35 | Requires enrollment in state obesity program |
| Minnesota | BMI ≥30 with diabetes or cardiovascular disease | Limited to 12 months initially |
| Washington | BMI ≥35, or BMI ≥30 with comorbidity | Requires prior auth, renewed every 6 months |
| Oregon | BMI ≥30 with comorbidity | Covers Wegovy and compounded semaglutide |
| Colorado | BMI ≥35 | Requires behavioral counseling participation |
| Connecticut | BMI ≥30 with comorbidity | Step therapy required (phentermine first) |
| Maryland | BMI ≥35 | Limited to patients under 65 |
| Vermont | BMI ≥30 with comorbidity | Requires 3-month trial of lifestyle intervention |
| Rhode Island | BMI ≥35 | Covers up to 24 months total |
| New Jersey | BMI ≥30 with diabetes | Diabetes-only pathway |
States that explicitly exclude Wegovy
The remaining 38 states plus D.C. exclude Wegovy from Medicaid formularies. Some states (Texas, Florida, Georgia, Ohio) exclude all weight-loss medications categorically. Others (Illinois, Pennsylvania, Michigan) exclude GLP-1s for weight loss but cover them for diabetes.
Why the split?
State Medicaid budgets are the constraint. Wegovy's list price is $1,349 per month. A state covering 100,000 Medicaid-eligible adults with obesity would face $1.6 billion in annual costs. Most states cannot or will not allocate that budget share to a single drug class.
The 12 states that cover Wegovy either have larger Medicaid budgets per capita (Massachusetts, New York) or have negotiated supplemental rebates with Novo Nordisk that lower the net cost below list price.
The employer self-funded plan variable
64% of American workers with employer-sponsored insurance are in self-funded plans (Kaiser Family Foundation 2025). This is the coverage variable most patients don't understand.
Fully insured vs self-funded.
In a fully insured plan, the employer pays premiums to an insurance carrier (UnitedHealthcare, Aetna, etc.), and the carrier assumes the financial risk. The carrier's formulary applies.
In a self-funded plan, the employer assumes the financial risk and pays claims directly. The carrier (UnitedHealthcare, Aetna, etc.) is hired as a third-party administrator (TPA) to process claims, but the employer decides what's covered.
A self-funded employer can take the UnitedHealthcare standard formulary and remove Wegovy. The patient still has a UnitedHealthcare insurance card, but Wegovy isn't covered.
Real-world employer decisions.
A 2025 survey of 800 large employers by the Business Group on Health found:
- 28% of employers cover GLP-1s for weight loss (up from 19% in 2024)
- 41% cover GLP-1s for diabetes only
- 31% exclude GLP-1s for weight loss entirely
Among employers that cover GLP-1s for weight loss, 73% require prior authorization, 52% require participation in a lifestyle program, and 38% impose annual or lifetime dollar caps ($5,000 to $15,000 per year).
How to find out if your employer plan covers Wegovy.
Call the member services number on your insurance card and ask: "Is Wegovy on my plan's formulary?" Do not ask "Does UnitedHealthcare cover Wegovy?" The answer to the second question is yes, but it may not apply to your specific plan.
Prior authorization requirements and denial rates
Even when a plan covers Wegovy, most patients face prior authorization.
Standard PA criteria across commercial plans (2026):
- BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
- Age 18 or older (some plans 21 or older)
- Documented weight-loss attempt in the past 12 months (behavioral program, commercial weight-loss program, or prescription weight-loss medication)
- No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, breastfeeding)
- Prescription from a licensed provider (MD, DO, NP, PA in most states)
Why 40-60% of PA requests are denied initially.
The most common denial reasons from a 2025 analysis of 12,000 Wegovy PA requests (Hendricks et al., Obesity 2025):
- Insufficient documentation of prior weight-loss attempt (34% of denials). The plan requires proof of a 12-week behavioral program or 3-month trial of another medication. The provider submits a PA without attaching documentation.
- BMI doesn't meet threshold (22% of denials). Patient has BMI 26.8 without a documented comorbidity, or the comorbidity isn't on the plan's approved list.
- Prescription written by an out-of-network provider (18% of denials). Some plans require the prescriber to be in-network.
- Plan excludes Wegovy entirely (14% of denials). The PA is submitted to a self-funded employer plan that removed Wegovy from the formulary.
- Missing labs or clinical notes (12% of denials). Plan requires recent A1C, lipid panel, or blood pressure readings to document comorbidity.
Appeals work.
Of the denied PAs that are appealed, 62% are approved on first appeal (Hendricks et al., Obesity 2025). The appeal process requires the provider to submit additional documentation, often the missing piece from the initial request.
What "coverage" actually means (formulary tiers and real costs)
A plan can "cover" Wegovy and still leave the patient with a $500 monthly copay.
Formulary tiers determine out-of-pocket cost.
Most plans use a 4- or 5-tier formulary:
- Tier 1: Generic drugs, $5 to $15 copay
- Tier 2: Preferred brand drugs, $30 to $75 copay
- Tier 3: Non-preferred brand drugs, $75 to $150 copay
- Tier 4: Specialty drugs, 20% to 40% coinsurance (you pay a percentage of the negotiated price)
- Tier 5: Specialty tier with higher coinsurance, sometimes 40% to 50%
Wegovy typically lands on Tier 4 or Tier 5. The negotiated price between the plan and the pharmacy is usually $1,100 to $1,200 per month. A patient with 30% coinsurance pays $330 to $360 per fill.
Deductibles apply first.
If your plan has a $3,000 deductible and you haven't met it, you pay the full negotiated price ($1,100 to $1,200) until the deductible is met. After that, the coinsurance applies.
For a patient on a high-deductible health plan, "coverage" means paying full price for the first 2-3 months, then paying 30% coinsurance for the rest of the year.
Out-of-pocket maximums cap total spending.
Once you've spent your plan's out-of-pocket maximum ($5,000 to $9,000 for individual coverage in most plans), the plan pays 100%. For patients on Wegovy year-round, this usually happens by mid-year.
The Novo Nordisk savings card doesn't apply to Wegovy.
Novo Nordisk offers a savings card for Ozempic (for diabetes) that reduces copays to $25 per month. There is no equivalent savings card for Wegovy. Novo Nordisk discontinued the Wegovy savings card in 2023 due to supply constraints and has not reintroduced it as of April 2026.
TRICARE, VA, and federal employee plans
TRICARE (military health coverage).
TRICARE covers Wegovy for active-duty service members and beneficiaries with prior authorization. Criteria include BMI ≥30 or BMI ≥27 with comorbidity. TRICARE's formulary is managed by Express Scripts. Copay for Wegovy is $29 per month for network pharmacies, $68 for non-network.
TRICARE is one of the most generous payers for Wegovy relative to copay cost.
Veterans Affairs (VA).
The VA covers Wegovy for veterans enrolled in VA healthcare. The VA added Wegovy to its national formulary in 2024. Prior authorization is required. Copay is $0 to $11 depending on the veteran's priority group and disability rating.
Federal Employee Health Benefits (FEHB) plans.
FEHB plans are administered by private carriers (BlueCross, Aetna, UnitedHealthcare) but follow OPM guidance. Most FEHB plans cover Wegovy with prior authorization. The Federal Employees Health Benefits Program issued guidance in 2024 encouraging coverage for obesity medications, and most carriers complied.
Copays vary by plan but are typically Tier 4 specialty, meaning 20-30% coinsurance.
The FormBlends Coverage Decision Framework
We built a decision framework for patients trying to determine whether pursuing insurance coverage for Wegovy makes sense compared to paying out-of-pocket for compounded semaglutide.
The 4-Gate Coverage Decision Model.
Gate 1: Does your plan's formulary include Wegovy?
Call your insurance member services or check your plan's online formulary. Search for "semaglutide" and "Wegovy." If it's not listed, stop here. Your plan doesn't cover it. Move to the compounded pathway.
Gate 2: Can you meet the prior authorization criteria?
Review your plan's PA criteria (available on the insurance website or by calling). Do you have the required BMI? Do you have documented comorbidities? Have you tried another weight-loss intervention in the past 12 months? If no to any of these, PA will likely be denied. Consider whether appealing is worth the 4-8 week delay.
Gate 3: Is your out-of-pocket cost sustainable?
Even if PA is approved, calculate your actual cost. If your plan has a $3,000 deductible and 30% coinsurance, your first fill costs $1,200, and subsequent fills cost $360. Over 12 months, that's $5,160. Compare this to $179 to $279 per month for compounded semaglutide ($2,148 to $3,348 annually).
Gate 4: Is the approval timeline acceptable?
PA approval takes 5 to 14 business days on average. If denied, the appeal takes another 14 to 30 days. If you need to start treatment within 2 weeks, insurance coverage may not be the fastest path.
Decision output:
- All 4 gates pass: Pursue insurance coverage.
- Gate 1 or 2 fails: Move to compounded semaglutide or pay cash.
- Gate 3 fails (cost too high): Compare total annual cost of insurance pathway vs compounded. Often compounded is cheaper.
- Gate 4 fails (timeline too long): Start with compounded, then transition to Wegovy if PA is later approved.
[Diagram suggestion: Flowchart with 4 decision diamonds, each gate labeled, with "pursue insurance" and "consider compounded" endpoints]
When coverage exists but access doesn't
A pattern we see consistently in FormBlends intake data: patients whose insurance "covers" Wegovy but who cannot access it.
The prior authorization denial loop.
Patient submits PA. Denied for insufficient documentation. Provider resubmits with additional notes. Denied for missing lab work. Provider orders labs, resubmits. Denied because the lab is older than 90 days. Provider orders new labs, resubmits. Approved, but 12 weeks have passed.
By the time approval comes through, some patients have either paid out-of-pocket for compounded semaglutide or given up entirely.
The pharmacy stock-out problem.
Even with an approved PA, the pharmacy may not have Wegovy in stock. Novo Nordisk has managed supply tightly since 2021. Periodic shortages, especially of the 1.7 mg and 2.4 mg doses, mean patients with valid prescriptions wait weeks for fills.
In Q4 2025, the FDA shortage database listed Wegovy 1.7 mg and 2.4 mg as "currently in shortage" for 6 consecutive weeks.
The reauthorization burden.
Most plans require PA reauthorization every 6 to 12 months. The patient must prove ongoing medical necessity, often including documented weight loss. If the patient hasn't lost at least 5% of baseline body weight, some plans deny reauthorization.
This creates a perverse incentive: patients who respond slowly to Wegovy (a known phenomenon, with some patients taking 6-9 months to see significant results) lose coverage before the medication has had time to work.
When you should NOT pursue insurance coverage for Wegovy
The strongest argument against pursuing insurance coverage, even when it exists:
Time cost exceeds financial savings.
If your plan requires 3 PA submissions, 2 appeals, and 16 weeks of back-and-forth, and your out-of-pocket cost after approval is $300 per month, you've spent 4 months without treatment to save $80 per month compared to starting compounded semaglutide immediately at $220 per month.
The 16 weeks of delay represent 16 weeks of continued obesity-related health risk, 16 weeks without the cardiovascular benefits demonstrated in SELECT, and 16 weeks of diminished quality of life.
For some patients, paying $220 per month starting today is the better clinical decision than fighting for $300 per month starting in 4 months.
When your plan's coverage is unstable.
Self-funded employer plans can change formularies mid-year. If your employer is considering removing Wegovy from the formulary (this happened to 14% of covered lives in 2025 per the Business Group on Health), starting treatment on insurance means risking a mid-treatment formulary change that forces you to either stop or switch to out-of-pocket payment.
Starting on compounded semaglutide from day one eliminates this risk.
When you value medication consistency.
Brand-name Wegovy and compounded semaglutide are not interchangeable. Switching between them mid-treatment requires re-titration in some cases. If you start on Wegovy through insurance, lose coverage 6 months later, and switch to compounded, you may experience a temporary efficacy gap during the transition.
Patients who prioritize treatment consistency sometimes choose compounded from the start to avoid forced switches.
The compounded semaglutide pathway
For patients whose insurance doesn't cover Wegovy, whose PA is denied, or whose out-of-pocket cost is unsustainable, compounded semaglutide is the most common alternative.
Pricing comparison (April 2026):
| Option | Monthly cost | Annual cost |
|---|---|---|
| Wegovy with insurance (average copay) | $150 to $400 | $1,800 to $4,800 |
| Wegovy cash price (no insurance) | $1,349 | $16,188 |
| FormBlends compounded semaglutide | $179 to $279 | $2,148 to $3,348 |
| Other telehealth compounded semaglutide | $199 to $499 | $2,388 to $5,988 |
Key differences:
- Compounded semaglutide is not FDA-approved
- It's prepared by a state-licensed 503A or 503B compounding pharmacy
- It's typically drawn from a vial with a syringe rather than delivered by a pre-filled pen
- It's chemically identical to the semaglutide in Wegovy but hasn't undergone the same manufacturing and stability testing
When compounded makes sense:
- Your insurance doesn't cover Wegovy
- Your PA was denied and appeals failed
- Your copay exceeds $250 per month
- You want predictable pricing without annual formulary risk
- You're comfortable with compounded medications
When brand-name Wegovy makes sense:
- Your copay is under $100 per month
- You strongly prefer FDA-approved medications
- You want the convenience of a pre-filled pen
- Your insurance coverage is stable (large employer, not at risk of formulary change)
The decision is patient-specific and should be made with a licensed provider who understands your clinical situation and financial constraints.
FAQ
What insurance covers Wegovy? Most major commercial insurance carriers (BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna, Humana) cover Wegovy on their standard formularies with prior authorization. However, coverage depends on your specific plan. Self-funded employer plans may exclude Wegovy even if the carrier's standard formulary includes it.
Does Medicare cover Wegovy? No. Medicare Part D cannot cover Wegovy by federal law. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 excludes coverage for weight-loss medications. This applies to both traditional Medicare and Medicare Advantage plans.
Does Medicaid cover Wegovy? Coverage varies by state. As of April 2026, 12 states cover Wegovy with prior authorization (California, New York, Massachusetts, Minnesota, Washington, Oregon, Colorado, Connecticut, Maryland, Vermont, Rhode Island, New Jersey). The remaining 38 states exclude it.
Does Blue Cross Blue Shield cover Wegovy? Most BCBS plans cover Wegovy with prior authorization, typically on Tier 4 specialty. However, BCBS operates as 35 independent companies, and coverage varies by state and plan. Employer self-funded plans administered by BCBS can exclude Wegovy.
Does UnitedHealthcare cover Wegovy? UnitedHealthcare's standard commercial formulary includes Wegovy with prior authorization. However, about 70% of UnitedHealthcare members are in self-funded employer plans that can exclude Wegovy. Check your specific plan's formulary.
Why was my Wegovy prior authorization denied? The most common denial reasons are insufficient documentation of prior weight-loss attempts (34% of denials), BMI below the plan's threshold (22%), out-of-network prescriber (18%), plan exclusion (14%), and missing labs or clinical notes (12%). Most denials can be appealed successfully with additional documentation.
How much does Wegovy cost with insurance? Out-of-pocket cost ranges from $25 to $500 per month depending on your formulary tier, deductible status, and coinsurance percentage. The most common range is $150 to $400 per month for patients on Tier 4 specialty with 20-30% coinsurance.
Does TRICARE cover Wegovy? Yes. TRICARE covers Wegovy for active-duty service members and beneficiaries with prior authorization. Copay is $29 per month at network pharmacies. TRICARE is one of the most generous payers for Wegovy.
Does the VA cover Wegovy? Yes. The VA added Wegovy to its national formulary in 2024. Prior authorization is required. Copay is $0 to $11 depending on the veteran's priority group and disability rating.
Can I use a Wegovy savings card with insurance? No. Novo Nordisk discontinued the Wegovy savings card in 2023 and has not reintroduced it as of April 2026. There is currently no manufacturer copay assistance program for Wegovy (unlike Ozempic, which has an active savings card).
What if my insurance covers Ozempic but not Wegovy? Ozempic is FDA-approved for type 2 diabetes, not weight loss. If you have type 2 diabetes, your provider can prescribe Ozempic, and insurance will cover it. Using Ozempic off-label for weight loss without a diabetes diagnosis may result in claim denial or audit.
How long does Wegovy prior authorization take? Initial PA decisions typically take 5 to 14 business days. If denied and appealed, the appeal process takes an additional 14 to 30 days. Urgent appeals can be expedited to 72 hours in some cases, but weight management is rarely classified as urgent.
Does insurance cover Wegovy for prediabetes? Most plans require either BMI ≥30 alone or BMI ≥27 with a weight-related comorbidity. Prediabetes (A1C 5.7-6.4%) qualifies as a comorbidity under most plans' criteria. However, the provider must document the prediabetes diagnosis with recent lab work.
What happens if I lose insurance coverage while on Wegovy? You can transition to paying cash ($1,349 per month), switch to compounded semaglutide ($179 to $279 per month), or stop treatment. Transitioning to compounded semaglutide is the most common pathway and usually requires re-titration under provider supervision.
Can I appeal a Wegovy prior authorization denial? Yes. Appeals are successful 62% of the time when additional documentation is submitted. Your provider submits the appeal with missing documentation (prior weight-loss attempt records, lab work, clinical notes). The appeal process takes 14 to 30 days on average.
Sources
- Wilkinson LR et al. Prior authorization denial rates for GLP-1 receptor agonists in commercial insurance. Health Affairs. 2025.
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023.
- Thompson KM et al. Medicare Part D claims audits for off-label semaglutide prescribing. JAMA Health Forum. 2025.
- Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
- Business Group on Health. Large Employer Health Care Strategy and Plan Design Survey. 2025.
- Hendricks EJ et al. Prior authorization outcomes for anti-obesity medications: A multi-payer analysis. Obesity. 2025.
- Novo Nordisk. Wegovy prescribing information. 2024.
- U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
- Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
- Congressional Budget Office. Cost estimate for H.R. 1577, Treat and Reduce Obesity Act. 2025.
- Office of Personnel Management. Federal Employees Health Benefits Program carrier letter on obesity medication coverage. 2024.
- Express Scripts. National Preferred Formulary. 2026.
- Department of Veterans Affairs. VA National Formulary. 2024.
- 42 U.S.C. § 1395w-102(e)(2)(A). Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna, and Humana are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →